title: [Comparison of efficiency and toxicity of two chemotherapy protocols in treatment of advanced non-small cell lung cancer].
abstract: BACKGROUND
  This study was aimed at comparing the efficiency and tolerability of two reference protocols Cisplatin and Etoposide and Cisplatin and Vinorelbine in advanced Non-Small Cell Lung Cancer.
  
  
  METHODS
  A total of 60 patients (two groups consisting of 30 patients) were treated for advanced Non-Small Cell Lung Cancer during the period from January to December 2005 according to the reference protocols (Cisplatin 100 mg/m2 D1; Vinorelbine 30 mg/m2 D1, D8 on 4 weeks) and (Cisplatin 100 mg/m D1; Etoposide 100 mg/m2 D1, D3, D5 on 4 weeks) at the Department of Oncology of KBC "Bezanijska kosa". All patients were analysed for tumour response, progression free survival as well as for toxicity. X2 test, Kaplan Meiers curves and Log rank test were used for statistical analysis.
  
  
  RESULTS
  Although the recorded response rates were a bit lower than in previously published trials, they were not significantly different p = 0.485. No statistically significant difference was recorded in either progression free survival or overall survival. The chemotherapeutical Cisplatin/Etoposide protocol proved to be more toxic both in hematologic (3% vs. 10%) and total toxicities (p = 0.047).
  
  
  CONCLUSIONS
  Our study proved both protocols to have equivalent efficacy. However, the Cisplatin, Vinorelbine protocol could be recommended because of its less expressed toxic effects.
authors.affiliation: Kantonalna bolnica Zenica, Odjel za onkologiju, Bosna i Hercegovina. dralmaa@hotmail.com
authors.forename: Alma Mekić
authors.initials: AM
authors.lastname: Abazović
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Sisić
authors.forename: Vladimir
authors.initials: V
authors.lastname: Kovcin
authors.forename: Hakija
authors.initials: H
authors.lastname: Beculić
authors.forename: Senad
authors.initials: S
authors.lastname: Dervisević
authors.forename: Miralem
authors.initials: M
authors.lastname: Musić
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D005047:Etoposide; D002945:Cisplatin; D000077235:Vinorelbine